Party insiders and backroom deals: One author on why we need to bring back old-time politics.
The Food and Drug Administration’s approval of the abortion drug RU-486 sparked a new round of debate between pro-life and pro-choice activists, but it also brought forth a new discussion about the drug’s medical benefits and drawbacks, who will be allowed to administer it, and how states will regulate its use. A panel talks about the new concerns raised by the introduction of RU-486 in the U.S.
- Richard Pierce professor of administrative law at George Washington University
- Dr. Mitchell Creinin physician
- Maxine Klane Planned Parenthood of Metropolitan Washington
Most Recent Shows
With a now-likely U.K. exit from the EU, America’s relationship with a key intelligence and global trade ally will change. Please join us to discuss what the British vote means for the U.S. economy, the 2016 presidential campaign and global security.
Analysis of the Supreme Court's last decisions of the term and the impact of a vacant seat on the bench.
The world reacts to Brexit: European Union leaders plan for Great Britain's departure and investors brace for more uncertainty, as the U.S. considers economic and strategic implications.